CRL
Charles River Laboratories Sets New Standards for Preclinical Drug Development in Q1 2025
Charles River Laboratories, a leading provider of preclinical drug development services, has reported impressive results in its First Quarter 2025 earnings call. The company's Vice President of Investor Relations, Todd Spencer, welcomed investors to the conference call, where he was joined by Jim Foster, Chair, President and Chief